Predictors of the 10-year direct costs for treating multiple sclerosis-Reference-Cited by-同舟云学术

Predictors of the 10-year direct costs for treating multiple sclerosis

Published:2016-06-29 Issue:5 Volume:135 Page:522-528
ISSN:0001-6314
Container-title:Acta Neurologica Scandinavica
language:en
Short-container-title:Acta Neurol Scand

Author:

Moccia M.¹,Palladino R.²³,Lanzillo R.¹,Triassi M.³,Brescia Morra V.¹

Affiliation:

1. Multiple Sclerosis Clinical Care and Research Centre; Department of Neuroscience, Reproductive Science and Odontostomatology; Federico II University; Naples Italy

2. Department of Primary Care and Public Health; Imperial College; London UK

3. Department of Public Health; Federico II University; Naples Italy

Publisher

Wiley

Subject

Clinical Neurology,Neurology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ane.12630/fullpdf

Reference36 articles.

1. Cost-effectiveness of disease-modifying therapies in multiple sclerosis;Manouchehrinia;Curr Neurol Neurosci Rep,2012

2. The socioeconomic consequences of optic neuritis with and without multiple sclerosis: a controlled national study;Jennum;Acta Neurol Scand,2013

3. Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs;Ponzio;Neurol Sci,2015

4. Economic burden of multiple sclerosis: a systematic review of the literature;Naci;Pharmacoeconomics,2010

5. The economic burden of Medicare-eligible patients by multiple sclerosis type;Gilden;Value Health,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between brain volume loss and disability in multiple sclerosis: A systematic review;Multiple Sclerosis and Related Disorders;2023-06

2. Determinants of early working impairments in multiple sclerosis;Frontiers in Neurology;2022-12-09

3. The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis;Journal of Medical Economics;2021-01-01

4. The Framingham cardiovascular risk score and 5‐year progression of multiple sclerosis;European Journal of Neurology;2020-11-21

5. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy);BMC Health Services Research;2020-08-26